Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
Kristina JeneiDaniel E MeyersPublished in: BMJ open (2023)
Clinicians offer crucial information on funding decisions. However, we found clinicians strongly supported funding nearly all cancer drugs under review, despite most not offering substantial benefit to patients nor gains in quality of life. While these drugs might be helpful options in clinical practice, funding numerous cancer drugs may be unsustainable for public health systems.
Keyphrases
- papillary thyroid
- clinical practice
- squamous cell
- end stage renal disease
- palliative care
- healthcare
- chronic kidney disease
- newly diagnosed
- squamous cell carcinoma
- lymph node metastasis
- emergency department
- physical activity
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- health information
- social media